Female infertility. Female infertility, unspecified
Conditions
Interventions
Intervention 1: Intervention: Foropin group: 150 - 300 units per day of Foropin by Humer Novin Daroo (based on previous menstrual assessment and ovarian sonography) will be administered subcutaneously
Sponsors
Humer Novin Daroo Co.
Eligibility
Sex/Gender
Female
Age
18 Years to 38 Years
Inclusion criteria
Inclusion criteria: Iranian female suffering infertility referring for IVF Age range: 18 - 38 years old Body Mass Index: 18 - 30 Kg/m2 Regular menstrual periods (25 - 35 days) Normal result based trans vaginal sonography at 2- 4 days of menstrual period at past 6 months Normal respondent to ovarian stimulating methods (10 -15 follicle with 3-8 mm diameter in two ovaries administering AFC or AMH more than 1.2 ng/mL in at least two cycles) Signing informed consent
Exclusion criteria
Exclusion criteria: Severe endometriosis (grade 3 or 4) Endocrine system impairments (Uncontrolled thyroid dysfunction, adrenal disease or uncorrected hyper-prolactinemia) Severe current smokers (more than 15 cigarette or 1 hookah per day) Previous hypersensitivity (e.g. OHSS) to Gonal-f or other FSH products Hepatic dysfunction (ALT or AST> 2 times the upper limit of normal) History of more than 2 unsuccessful IVF Any hormone therapy during past month (levothyroxine is exception) Azoospermia in husband confirmed by semen analysis History for suffering from any cancer Lactation during study History of previous uterine or ovarian surgery
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The number of oocytes in MII phase at the day of oocyte retrieval. Timepoint: At the end of intervention. Method of measurement: Embryologic assessments. | — |
Secondary
| Measure | Time frame |
|---|---|
| The percent of mature oocyte in total oocytes retrieved. Timepoint: At the end of intervention. Method of measurement: Embryological assessment.;Total dose of administered rhFSH. Timepoint: At the end of intervention. Method of measurement: Patients' medical record.;Retrieved oocytes quality. Timepoint: At the end of intervention. Method of measurement: Embryological assessment.;Fertilization rate in oocytes. Timepoint: At the end of intervention. Method of measurement: Embryological assessment.;Chemical pregnancy. Timepoint: Two weeks after embryo transfer. Method of measurement: Beta HCG test.;Clinical pregnancy. Timepoint: 5-6 weeks after embryo transfer. Method of measurement: Ultrasonography.;Ovarian hyperstimulation syndrome (OHSS). Timepoint: During intervention. Method of measurement: Ultrasonography.;Thromboembolism. Timepoint: During intervention. Method of measurement: Clinical examination and patients record.;Unwanted serous events related to study medication. Timepoint: During and at the end of intervention. Method of measurement: Patients' medical records.;Embryo quality. Timepoint: At the end of intervention. Method of measurement: Embryological assessment. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Ramin Heshmat
Tehran University of Medical Sciences
Outcome results
None listed